Hepatitis C and hepatocellular carcinoma

New developments in natural history and treatment

Joseph Ahn, Steven L. Flamm

Research output: Contribution to journalArticle

Abstract

The incidence of hepatocellular carcinoma (HCC) associated with chronic hepatitis C virus (HCV) infection doubled over the past 20 years in the United States because of an increase in cirrhosis related to HCV and other factors, including diabetes mellitus. Survival after HCC diagnosis remains relatively unchanged, with a persistently high mortality rate. Primary prevention of HCC by treatment of HCV is supported by multiple, large, retrospective studies. Despite significant methodologic limitations, the studies indicate a benefit of HCC reduction with therapy. Sustained virologic response appears to provide the greatest protection against HCC development. Alternatively, a large, randomized, controlled trial showed that maintenance HCV treatment in patients with advanced fibrosis and cirrhosis does not decrease HCC incidence. Secondary prevention of HCC in HCV patients with established HCC who have undergone primary resection or liver-directed therapy appears beneficial only in reducing the risk of late HCC recurrence.

Original languageEnglish (US)
Pages (from-to)59-65
Number of pages7
JournalCurrent Hepatitis Reports
Volume8
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Hepatitis C
Natural History
Hepatocellular Carcinoma
Hepacivirus
Fibrosis
Therapeutics
Incidence
Chronic Hepatitis C
Virus Diseases
Primary Prevention
Secondary Prevention
Diabetes Mellitus
Randomized Controlled Trials
Retrospective Studies
Maintenance
Recurrence
Survival
Mortality
Liver

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Hepatitis C and hepatocellular carcinoma : New developments in natural history and treatment. / Ahn, Joseph; Flamm, Steven L.

In: Current Hepatitis Reports, Vol. 8, No. 2, 2009, p. 59-65.

Research output: Contribution to journalArticle

@article{78bf4680487744a49cea2997dfe32e6e,
title = "Hepatitis C and hepatocellular carcinoma: New developments in natural history and treatment",
abstract = "The incidence of hepatocellular carcinoma (HCC) associated with chronic hepatitis C virus (HCV) infection doubled over the past 20 years in the United States because of an increase in cirrhosis related to HCV and other factors, including diabetes mellitus. Survival after HCC diagnosis remains relatively unchanged, with a persistently high mortality rate. Primary prevention of HCC by treatment of HCV is supported by multiple, large, retrospective studies. Despite significant methodologic limitations, the studies indicate a benefit of HCC reduction with therapy. Sustained virologic response appears to provide the greatest protection against HCC development. Alternatively, a large, randomized, controlled trial showed that maintenance HCV treatment in patients with advanced fibrosis and cirrhosis does not decrease HCC incidence. Secondary prevention of HCC in HCV patients with established HCC who have undergone primary resection or liver-directed therapy appears beneficial only in reducing the risk of late HCC recurrence.",
author = "Joseph Ahn and Flamm, {Steven L.}",
year = "2009",
doi = "10.1007/s11901-009-0009-7",
language = "English (US)",
volume = "8",
pages = "59--65",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "2",

}

TY - JOUR

T1 - Hepatitis C and hepatocellular carcinoma

T2 - New developments in natural history and treatment

AU - Ahn, Joseph

AU - Flamm, Steven L.

PY - 2009

Y1 - 2009

N2 - The incidence of hepatocellular carcinoma (HCC) associated with chronic hepatitis C virus (HCV) infection doubled over the past 20 years in the United States because of an increase in cirrhosis related to HCV and other factors, including diabetes mellitus. Survival after HCC diagnosis remains relatively unchanged, with a persistently high mortality rate. Primary prevention of HCC by treatment of HCV is supported by multiple, large, retrospective studies. Despite significant methodologic limitations, the studies indicate a benefit of HCC reduction with therapy. Sustained virologic response appears to provide the greatest protection against HCC development. Alternatively, a large, randomized, controlled trial showed that maintenance HCV treatment in patients with advanced fibrosis and cirrhosis does not decrease HCC incidence. Secondary prevention of HCC in HCV patients with established HCC who have undergone primary resection or liver-directed therapy appears beneficial only in reducing the risk of late HCC recurrence.

AB - The incidence of hepatocellular carcinoma (HCC) associated with chronic hepatitis C virus (HCV) infection doubled over the past 20 years in the United States because of an increase in cirrhosis related to HCV and other factors, including diabetes mellitus. Survival after HCC diagnosis remains relatively unchanged, with a persistently high mortality rate. Primary prevention of HCC by treatment of HCV is supported by multiple, large, retrospective studies. Despite significant methodologic limitations, the studies indicate a benefit of HCC reduction with therapy. Sustained virologic response appears to provide the greatest protection against HCC development. Alternatively, a large, randomized, controlled trial showed that maintenance HCV treatment in patients with advanced fibrosis and cirrhosis does not decrease HCC incidence. Secondary prevention of HCC in HCV patients with established HCC who have undergone primary resection or liver-directed therapy appears beneficial only in reducing the risk of late HCC recurrence.

UR - http://www.scopus.com/inward/record.url?scp=65549099599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65549099599&partnerID=8YFLogxK

U2 - 10.1007/s11901-009-0009-7

DO - 10.1007/s11901-009-0009-7

M3 - Article

VL - 8

SP - 59

EP - 65

JO - Current Hepatitis Reports

JF - Current Hepatitis Reports

SN - 1540-3416

IS - 2

ER -